Keyphrases
Pediatric Cancer Patients
72%
Pediatric
68%
Pediatric Oncology
52%
Oncology Patients
48%
Delayed Clearance
45%
High-dose Methotrexate (HD-MTX)
45%
Young Adult Oncology
45%
Infectious Complications
45%
Risk Factors
42%
Oncology
22%
Vascular Anomalies
22%
Sirolimus
22%
Adverse Events
22%
Risk Priority number
22%
Transplant Patients
22%
L-asparaginase
22%
Bloodstream Infection
22%
Evaluating Risks
22%
Apologizing
22%
Clostridium Difficile Infection
22%
Inpatient Pediatrics
22%
Stem Cell Transplantation
22%
Acute Lymphoblastic Leukemia
22%
Quality Improvement Effort
22%
Osteopathia Striata with Cranial Sclerosis
22%
Epileptic Encephalopathy
22%
Failure Mode Effect Analysis
22%
Phenotypic Spectrum
22%
Therapeutic Program
22%
Wilms Tumor
22%
Program Design
22%
Clinical Spectrum
22%
Uridine
22%
Failure Mode
22%
Hyperammonemia
22%
123I-MIBG
22%
Iodine-131 (131I)
22%
Central Line-associated Bloodstream Infection (CLABSI)
22%
Reading Acuity
22%
Speed Evaluation
22%
Children's Oncology Group
22%
Survey Assessment
22%
Length of Stay
17%
Fever
17%
Clinical Practice Guidelines
17%
Uridine Monophosphate
15%
Developmental Delay
15%
Status Epilepticus
15%
Neonatal Seizures
15%
Intellectual Disability
15%
Medicine and Dentistry
Childhood Cancer
100%
Oncology
73%
Pediatrics
68%
Drug Megadose
45%
Methotrexate
45%
Adolescence
45%
Infectious Complication
45%
Infection
42%
Quality Improvement
34%
Acute Lymphoblastic Leukemia
27%
Adverse Event
26%
Bloodstream Infection
26%
Pediatrics Patient
24%
Vascular Anomaly
22%
Cohort Analysis
22%
Systematic Review
22%
Uridine Phosphate
22%
Stem Cell Transplant
22%
Rapamycin
22%
Infantile Spasm
22%
Developmental Delay
22%
Osteopathia striata
22%
Catheter Infection
22%
Supplementation
22%
Hyperammonemia
22%
Sclerosis
22%
Asparaginase
22%
Wilms' Tumor
22%
(3 Iodobenzyl)guanidine
22%
Status Epilepticus
22%
Iodine 131
22%
Brain Disease
22%
Antiinfective Agent
22%
Neoplasm
18%
Infection Prevention
14%
Patient Safety
13%
Genetic Screening
13%
Uridine Triacetate
11%
Adverse Outcome
11%
Patient Experience
11%
Pneumocystis Jirovecii
11%
Congenital Dyserythropoietic Anemia
11%
Biological Marker
11%
Newborn Screening
11%
Stereotypic Movement Disorder
11%
Anemia
11%
Fibroblast
11%
Pyrimidine
11%
Diseases
11%
Central Venous Catheter
10%
